{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["11(6)"],"submitter":["Ogdie A"],"funding":["Pfizer"],"pubmed_abstract":["<h4>Introduction</h4>Routine care studies of psoriatic arthritis (PsA) and ankylosing spondylitis (AS) demonstrated attenuated responses to tumor necrosis factor inhibitors in current/past versus never smokers. This post hoc analysis assessed tofacitinib efficacy and safety in patients with PsA or AS by cigarette smoking status at trial screening.<h4>Methods</h4>Pooled data from phase 3 and long-term extension (safety only) PsA trials and phase 2 and 3 AS trials were assessed by current/past versus never smoker status. Analysis included efficacy and safety data for tofacitinib 5 (PsA/AS) and 10 (PsA only) mg twice daily (BID) or placebo, and safety data in AS for tofacitinib 2 and 10 mg BID. Efficacy outcomes included American College of Rheumatology ≥ 50% responses (ACR50) and minimal dis"],"journal":["Rheumatology and therapy"],"pagination":["1649-1664"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11557744"],"repository":["biostudies-literature"],"pubmed_title":["Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis or Ankylosing Spondylitis by Cigarette Smoking Status."],"pmcid":["PMC11557744"],"pubmed_authors":["Gruben D","Akar S","Kinch CD","Kristensen LE","Fallon L","Ogdie A","Soriano ER","Gladman DD","Sun Y"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis or Ankylosing Spondylitis by Cigarette Smoking Status.","description":"<h4>Introduction</h4>Routine care studies of psoriatic arthritis (PsA) and ankylosing spondylitis (AS) demonstrated attenuated responses to tumor necrosis factor inhibitors in current/past versus never smokers. This post hoc analysis assessed tofacitinib efficacy and safety in patients with PsA or AS by cigarette smoking status at trial screening.<h4>Methods</h4>Pooled data from phase 3 and long-term extension (safety only) PsA trials and phase 2 and 3 AS trials were assessed by current/past versus never smoker status. Analysis included efficacy and safety data for tofacitinib 5 (PsA/AS) and 10 (PsA only) mg twice daily (BID) or placebo, and safety data in AS for tofacitinib 2 and 10 mg BID. Efficacy outcomes included American College of Rheumatology ≥ 50% responses (ACR50) and minimal dis","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Dec","modification":"2026-06-03T03:22:41.076Z","creation":"2025-04-06T22:44:19.292Z"},"accession":"S-EPMC11557744","cross_references":{"pubmed":["39320582"],"doi":["10.1007/s40744-024-00711-z"]}}